Antenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program.
- Publisher:
- Wiley
- Publication Type:
- Journal Article
- Citation:
- Aust N Z J Obstet Gynaecol, 2022, 62, (1), pp. 168-171
- Issue Date:
- 2022-02
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
Aust NZ J Obst Gynaeco - 2021 - Keir - Antenatal magnesium sulphate for preventing cerebral palsy An economic evaluation.pdf | 189.73 kB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Keir, A | |
dc.contributor.author | Rumbold, A | |
dc.contributor.author | Shepherd, E | |
dc.contributor.author | Mcintyre, S | |
dc.contributor.author | Groves, C | |
dc.contributor.author | Cavallaro, A | |
dc.contributor.author | Crowther, C | |
dc.contributor.author |
Callander, E https://orcid.org/0000-0001-7233-6804 |
|
dc.date.accessioned | 2023-02-10T01:51:02Z | |
dc.date.available | 2021-10-31 | |
dc.date.available | 2023-02-10T01:51:02Z | |
dc.date.issued | 2022-02 | |
dc.identifier.citation | Aust N Z J Obstet Gynaecol, 2022, 62, (1), pp. 168-171 | |
dc.identifier.issn | 0004-8666 | |
dc.identifier.issn | 1479-828X | |
dc.identifier.uri | http://hdl.handle.net/10453/166034 | |
dc.description.abstract | Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Wiley | |
dc.relation | http://purl.org/au-research/grants/nhmrc/1159536 | |
dc.relation.ispartof | Aust N Z J Obstet Gynaecol | |
dc.relation.isbasedon | 10.1111/ajo.13459 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1114 Paediatrics and Reproductive Medicine, 1117 Public Health and Health Services | |
dc.subject.classification | Obstetrics & Reproductive Medicine | |
dc.subject.mesh | Cerebral Palsy | |
dc.subject.mesh | Child | |
dc.subject.mesh | Cost-Benefit Analysis | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Magnesium Sulfate | |
dc.subject.mesh | Neuroprotective Agents | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Premature Birth | |
dc.subject.mesh | Quality Improvement | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Cerebral Palsy | |
dc.subject.mesh | Premature Birth | |
dc.subject.mesh | Magnesium Sulfate | |
dc.subject.mesh | Neuroprotective Agents | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Child | |
dc.subject.mesh | Cost-Benefit Analysis | |
dc.subject.mesh | Female | |
dc.subject.mesh | Quality Improvement | |
dc.subject.mesh | Cerebral Palsy | |
dc.subject.mesh | Child | |
dc.subject.mesh | Cost-Benefit Analysis | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Magnesium Sulfate | |
dc.subject.mesh | Neuroprotective Agents | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Premature Birth | |
dc.subject.mesh | Quality Improvement | |
dc.title | Antenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program. | |
dc.type | Journal Article | |
utslib.citation.volume | 62 | |
utslib.location.activity | Australia | |
utslib.for | 1114 Paediatrics and Reproductive Medicine | |
utslib.for | 1117 Public Health and Health Services | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2023-02-10T01:51:00Z | |
pubs.issue | 1 | |
pubs.publication-status | Published | |
pubs.volume | 62 | |
utslib.citation.issue | 1 |
Abstract:
Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph